[FG] Läubli Heinz

Stuecheli, S. et al. (2025) ‘CAR T cell engineering impacts antigen-independent activation and co-inhibition’. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2025.01.20.631849.

Mangana, Johanna et al. (2024) ‘Gender differences in melanoma awareness, diagnosis and treatment: Patient-reported data from a multicentre survey in Switzerland’, Skin Health and Disease, 4(6). Available at: https://doi.org/10.1002/ski2.442.

Märkl, Florian et al. (2024) ‘Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia’, Nature Communications, 15(1). Available at: https://doi.org/10.1038/s41467-024-45378-w.

Mastall, Maximilian et al. (2024) ‘A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol’, BMC Cancer, 24(1). Available at: https://doi.org/10.1186/s12885-023-11797-z.

Saalfeld, Felix Carl et al. (2024) ‘Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy’, European Journal of Cancer, 213. Available at: https://doi.org/10.1016/j.ejca.2024.115065.

Brune, Magdalena M. et al. (2024) ‘MTAP as an emerging biomarker in thoracic malignancies’, Lung Cancer, 197. Available at: https://doi.org/10.1016/j.lungcan.2024.107963.

Wyss, Nina et al. (2024) ‘Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade’, American Journal of Respiratory and Critical Care Medicine, 210(7), pp. 919–930. Available at: https://doi.org/10.1164/rccm.202311-2136OC.

Freitag, Patrick C. et al. (2024) ‘DARPin-fused T cell engager for adenovirus-mediated cancer therapy’, Molecular Therapy Oncology, 32(3). Available at: https://doi.org/10.1016/j.omton.2024.200821.

Amaral, Margarida et al. (2024) ‘Paraneoplastischer subakut kutaner Lupus erythematodes’, Die Dermatologie. 05.03.2024, 75(7), pp. 568–571. Available at: https://doi.org/10.1007/s00105-024-05319-6.

König, David et al. (2024) ‘Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes’, Cancer Immunology Research, 12(7), pp. 814–821. Available at: https://doi.org/10.1158/2326-6066.CIR-23-0757.

Mantuano, Natalia Rodrigues and Läubli, Heinz (2024) ‘Sialic acid and Siglec receptors in tumor immunity and immunotherapy’, Seminars in Immunology, 74-75. Available at: https://doi.org/10.1016/j.smim.2024.101893.

De Joode, Karlijn et al. (2024) ‘Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients with Advanced Stage Melanoma’, Journal of Immunotherapy, 47(5), pp. 190–194. Available at: https://doi.org/10.1097/CJI.0000000000000506.

Filipsky, F. and Läubli, H. (2024) ‘Regulation of sialic acid metabolism in cancer’, Carbohydrate Research, 539. Available at: https://doi.org/10.1016/j.carres.2024.109123.

Pedram, K. et al. (2024) ‘Design of a mucin-selective protease for targeted degradation of cancer-associated mucins’, Nature Biotechnology, 42(4), pp. 597–607. Available at: https://doi.org/10.1038/s41587-023-01840-6.

Stadler, Christina et al. (2024) ‘Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older’, Neuro-Oncology Practice, 11(2), pp. 132–141. Available at: https://doi.org/10.1093/nop/npad070.

Chu, Chih-Wei et al. (2024) ‘Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors’, Life Science Alliance, 7(3). Available at: https://doi.org/10.26508/lsa.202302368.

Läubli, Heinz (2024) ‘Unraveling the impact of a glyco-immune checkpoint in bone metastasis’, Proceedings of the National Academy of Sciences of the United States of America, 121(9). Available at: https://doi.org/10.1073/pnas.2400499121.

Daetwyler, Eveline et al. (2024) ‘Corticosteroid-resistant immune-related adverse events: A systematic review’, Journal for ImmunoTherapy of Cancer, 12(1). Available at: https://doi.org/10.1136/jitc-2023-007409.

Melero, Ignacio et al. (2024) ‘Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours’, Nature [Preprint]. Available at: https://doi.org/10.1038/s41586-024-08305-z.

Conti, Gabriele et al. (2023) ‘Tetra- and Hexavalent Siglec-8 Ligands Modulate Immune Cell Activation’, Angewandte Chemie - International Edition. 09.11.2023, 62(52). Available at: https://doi.org/10.1002/anie.202314280.

Puttock, E.H. et al. (2023) ‘Extracellular matrix educates an immunoregulatory tumor macrophage phenotype found in ovarian cancer metastasis’, Nature Communications, 14(1). Available at: https://doi.org/10.1038/s41467-023-38093-5.

Joerger, Markus et al. (2023) ‘Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors’, Journal for ImmunoTherapy of Cancer, 11(11). Available at: https://doi.org/10.1136/jitc-2023-007784.

Bieberich, F. et al. (2023) Multimodal single-cell profiling of T cell specificity and reactivity in lung cancer. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2023.10.04.560863.

Läubli, H. (2023) ‘Cellular immunotherapies for malignancies - How do they work and what are the side effects?’, Therapeutische Umschau. Revue therapeutique, 80(8), pp. 348–352.

König, D. et al. (2023) ‘Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14’, ESMO Open, 8(4), p. 101595. Available at: https://doi.org/10.1016/j.esmoop.2023.101595.

Schumann K et al. (2023) ‘Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland’, Journal of the European Academy of Dermatology and Venereology, 37(5), pp. 894–906. Available at: https://doi.org/10.1111/jdv.18779.

Wallrabenstein, Till et al. (2023) ‘Real-World Data of Combined Immunochemotherapy in Patients With Nonsquamous Advanced NSCLC. A Single-Center Retrospective Study’, JTO Clinical and Research Reports, 4(5), p. 100509. Available at: https://doi.org/10.1016/j.jtocrr.2023.100509.

Stanczak MA and Läubli H (2023) ‘Siglec receptors as new immune checkpoints in cancer’, Molecular Aspects of Medicine, 90, p. 101112. Available at: https://doi.org/10.1016/j.mam.2022.101112.

Daetwyler, Eveline et al. (2023) ‘Pembrolizumab-induced optic neuropathy – a case report’, Frontiers in Immunology, 14. Available at: https://doi.org/10.3389/fimmu.2023.1171981.

Manni, Michela et al. (2023) ‘Detection of N-glycolyl-neuraminic acid-containing glycolipids in human skin’, Frontiers in Immunology, 14. Available at: https://doi.org/10.3389/fimmu.2023.1291292.

Müller, Benjamin et al. (2023) ‘Changes of peripheral T cell subsets in melanoma patients with immune-related adverse events’, Frontiers in Immunology, 14. Available at: https://doi.org/10.3389/fimmu.2023.1125111.

Schmassmann, P. et al. (2023) ‘Targeting the Siglec–sialic acid axis promotes antitumor immune responses in preclinical models of glioblastoma’, Science Translational Medicine, 15(705). Available at: https://doi.org/10.1126/scitranslmed.adf5302.

Castellanos-Rueda R et al. (2022) ‘speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing’, Nature Communications, 13(1), p. 6555. Available at: https://doi.org/10.1038/s41467-022-34141-8.

Läubli H, Nalle SC and Maslyar D (2022) ‘Targeting the Siglec–Sialic Acid Immune Axis in Cancer: Current and Future Approaches’, Cancer Immunology Research, 10(12), pp. 1423–1432. Available at: https://doi.org/10.1158/2326-6066.CIR-22-0366.

Panje C et al. (2022) ‘Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial’, European Journal of Cancer, 177, pp. 186–193. Available at: https://doi.org/10.1016/j.ejca.2022.09.035.

Kirchhammer N et al. (2022) ‘Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment’, Science Translational Medicine, 14(670), p. eabo3605. Available at: https://doi.org/10.1126/scitranslmed.abo3605.

Stanczak MA et al. (2022) ‘Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade’, Science Translational Medicine, 14(669), p. eabj1270. Available at: https://doi.org/10.1126/scitranslmed.abj1270.

Kaumanns, Anna et al. (2022) ‘Role of 18F-FDG PET/CT in the postoperative follow-up in patients with stage I-III NSCLC: A retrospective single-institution study’, Lung Cancer, 173, pp. 14–20. Available at: https://doi.org/10.1016/j.lungcan.2022.08.020.

Vazquez-Lombardi R et al. (2022) ‘High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity’, Immunity, 55(10), pp. 1953–1966.e10. Available at: https://doi.org/10.1016/j.immuni.2022.09.004.

Berner F et al. (2022) ‘Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade’, Science Immunology, 7(75), p. eabn9644. Available at: https://doi.org/10.1126/sciimmunol.abn9644.

Ruperti-Repilado, Francisco Javier et al. (2022) ‘Case report of elevation of high-sensitivity cardiac troponin T in the absence of cardiac involvement in immune checkpoint inhibitor-associated myositis’, European Heart Journal - Case Reports, 6(9), p. ytac353. Available at: https://doi.org/10.1093/ehjcr/ytac353.

Mandruzzato S and Läubli H (2022) ‘Editorial: Novel roles for tumor-associated neutrophils’, 13. Available at: https://doi.org/10.3389/fimmu.2022.1004772.

Beatson R et al. (2022) ‘Editorial: Glycans: Masters of immunity, from cancers to inflammatory disease’, 13. Available at: https://doi.org/10.3389/fimmu.2022.1002679.

König, David et al. (2022) ‘Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma’, Pharmacology, 107(7-8), pp. 433–438. Available at: https://doi.org/10.1159/000524399.

Zeitlberger AM et al. (2022) ‘Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis’, Journal of Neuro-Oncology, 158(3), pp. 359–367. Available at: https://doi.org/10.1007/s11060-022-04022-7.

König, D. et al. (2022) ‘Corrigendum to ‘Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials’: [ESMO Open Volume 7, Issue 2, (2022), 100455](S2059702922000710)(10.1016/j.esmoop.2022.100455)’, ESMO Open, 7(3), p. 100494. Available at: https://doi.org/10.1016/j.esmoop.2022.100494.

Wieboldt R and Läubli H (2022) ‘Glycosaminoglycans in cancer therapy’, American Journal of Physiology - Cell Physiology, 322(6), pp. C1187–C1200. Available at: https://doi.org/10.1152/ajpcell.00063.2022.

Kostner L et al. (2022) ‘Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during Lockdown’, Cancers, 14(10). Available at: https://doi.org/10.3390/cancers14102360.

König, D. et al. (2022) ‘Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials’, ESMO Open, 7(2). Available at: https://doi.org/10.1016/j.esmoop.2022.100455.

Wang, Jinyu et al. (2022) ‘Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer’, Frontiers in Cell and Developmental Biology, 10. Available at: https://doi.org/10.3389/fcell.2022.828916.

Kasenda, B. et al. (2022) ‘Targeting immunoliposomes to EGFR-positive glioblastoma’, ESMO Open, 7(1). Available at: https://doi.org/10.1016/j.esmoop.2021.100365.

Läubli, H. and Zippelius, A. (2022) ‘Tumor-infiltrating lymphocytes (TIL) therapy for malignant melanoma’, Tagliche Praxis, 65, pp. 620–629.

Laubli H. et al. (2021) ‘Tools to study and target the Siglec–sialic acid axis in cancer’, FEBS Journal, 288(21), pp. 6206–6225. Available at: https://doi.org/10.1111/febs.15647.

Werner F. et al. (2021) ‘Loss of lymphotoxin alpha-expressing memory b cells correlates with metastasis of human primary melanoma’, Diagnostics, 11(7). Available at: https://doi.org/10.3390/diagnostics11071238.

Werner F. et al. (2021) ‘A Standardized Analysis of Tertiary Lymphoid Structures in Human Melanoma: Disease Progression- and Tumor Site-Associated Changes With Germinal Center Alteration’, Frontiers in Immunology, 12, p. 675146. Available at: https://doi.org/10.3389/fimmu.2021.675146.

Hofer S et al. (2021) ‘Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM)’, Swiss medical weekly, 151, p. w20501. Available at: https://doi.org/10.4414/smw.2021.20501.

Gross MW, Laubli H. and Cordier D (2021) ‘Multidisciplinary tumor boards as videoconferences – a new challenge in the COVID-19 era’, 32(4). Available at: https://doi.org/10.1016/j.annonc.2021.01.002.

Kelly RJ et al. (2021) ‘Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer’, New England Journal of Medicine, 384(13), pp. 1191–1203. Available at: https://doi.org/10.1056/NEJMoa2032125.

Pantelyushin S. et al. (2021) ‘Cross-reactivity and functionality of approved human immune checkpoint blockers in dogs’, Cancers, 13(4), pp. 1–18. Available at: https://doi.org/10.3390/cancers13040785.

Läubli, H. and Zippelius, A. (2021) ‘Tumor-infiltrating lymphocytes (TIL) therapy for malignant melanoma’, Internistische Praxis, 64, pp. 456–464.

Manni M. and Laubli H. (2021) ‘Targeting glyco-immune checkpoints for cancer therapy’, Expert Opinion on Biological Therapy, 21(8), pp. 1063–1071. Available at: https://doi.org/10.1080/14712598.2021.1882989.

Gray MA et al. (2020) ‘Targeted glycan degradation potentiates the anticancer immune response in vivo’, Nature Chemical Biology, 16(12), pp. 1376–1384. Available at: https://doi.org/10.1038/s41589-020-0622-x.

Pearce O.M.T. and Laubli H. (2020) ‘A sweet approach to heat up cancer response to immunotherapy’, Cancer Discovery, 10(12), pp. 1789–1790. Available at: https://doi.org/10.1158/2159-8290.CD-20-1355.

Rodrigues Mantuano N et al. (2020) ‘Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy’, Journal for ImmunoTherapy of Cancer, 8(2). Available at: https://doi.org/10.1136/jitc-2020-001222.

Rodrigues Mantuano N et al. (2020) ‘Hyperglycemia enhances cancer immune evasion by inducing alternative macrophage polarization through increased O-GlcNAcylation’, Cancer Immunology Research, 8(10), pp. 1262–1272. Available at: https://doi.org/10.1158/2326-6066.CIR-19-0904.

Trefny MP et al. (2020) ‘PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade’, Cancer Immunology, Immunotherapy, 69(8), pp. 1505–1517. Available at: https://doi.org/10.1007/s00262-020-02558-z.

Trüb M et al. (2020) ‘Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer’, Journal for ImmunoTherapy of Cancer, 8(2). Available at: https://doi.org/10.1136/jitc-2019-000238.

Roth P et al. (2020) ‘A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults’, Swiss Medical Weekly, 150(23-24). Available at: https://doi.org/10.4414/smw.2020.20256.

Fehr M et al. (2020) ‘High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08’, BMC Cancer, 20(1), p. 166. Available at: https://doi.org/10.1186/s12885-020-6623-z.

Läubli H and Varki A (2020) ‘Sialic acid–binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses’, Cellular and Molecular Life Sciences, 77(4), pp. 593–605. Available at: https://doi.org/10.1007/s00018-019-03288-x.

Alborelli I et al. (2020) ‘Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer’, Journal of Pathology, 250(1), pp. 19–29. Available at: https://doi.org/10.1002/path.5344.

Trinh B, Donath MY and Läubli H (2020) ‘Successful treatment of immune checkpoint inhibitor-induced diabetes with infliximab. Diabetes Care 2019;42:e153-e154’, 43(1). Available at: https://doi.org/10.2337/dci19-0058.

Griss J et al. (2019) ‘B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma’, Nature Communications, 10(1), p. 4186. Available at: https://doi.org/10.1038/s41467-019-12160-2.

Bärenwaldt A and Läubli H (2019) ‘The sialoglycan-Siglec glyco-immune checkpoint–a target for improving innate and adaptive anti-cancer immunity’, Expert Opinion on Therapeutic Targets. 23.09.2019, 23(10), pp. 839–853. Available at: https://doi.org/10.1080/14728222.2019.1667977.

Liewen H et al. (2019) ‘Therapeutic Targeting of Golgi Phosphoprotein 2 (GOLPH2) with Armed Antibodies: A Preclinical Study of Anti-GOLPH2 Antibody Drug Conjugates in Lung and Colorectal Cancer Models of Patient Derived Xenografts (PDX)’, Targeted Oncology, 14(5), pp. 577–590. Available at: https://doi.org/10.1007/s11523-019-00667-z.

Kashyap AS et al. (2019) ‘GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses’, Cell Reports, 28(13), pp. 3367–3380.e8. Available at: https://doi.org/10.1016/j.celrep.2019.08.057.

Läubli H and Borsig L (2019) ‘Altered Cell Adhesion and Glycosylation Promote Cancer Immune Suppression and Metastasis’, Frontiers in Immunology, 10, p. 2120. Available at: https://doi.org/10.3389/fimmu.2019.02120.

Trinh B, Donath MY and Läubli H (2019) ‘Successful treatment of immune checkpoint inhibitor-induced diabetes with infliximab’, 42(9). Available at: https://doi.org/10.2337/dc19-0908.

Berner F et al. (2019) ‘Association of Checkpoint Inhibitor-Induced Toxic Effects with Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer’, JAMA Oncology, 5(7), pp. 1043–1047. Available at: https://doi.org/10.1001/jamaoncol.2019.0402.

Haas Q et al. (2019) ‘Siglec-9 Regulates an Effector Memory CD8þ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment’, Cancer Immunology Research, 7(5), pp. 707–718. Available at: https://doi.org/10.1158/2326-6066.cir-18-0505.

Cheng WC et al. (2019) ‘Publisher Correction: Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle.’, 20(4). Available at: https://doi.org/10.1038/s41590-019-0359-4.

Läubli H, Dirnhofer S and Zippelius A (2019) ‘Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy’, Virchows Archiv. 25.08.2018, 474(4), pp. 485–495. Available at: https://doi.org/10.1007/s00428-018-2435-9.

Streckmann F et al. (2019) ‘Individually tailored whole-body vibration training to reduce symptoms of chemotherapy-induced peripheral neuropathy: Study protocol of a randomised controlled trial-VANISH’, BMJ Open, 9(4), p. e024467. Available at: https://doi.org/10.1136/bmjopen-2018-024467.

Trinh B et al. (2019) ‘Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma’, Journal for ImmunoTherapy of Cancer, 7(1), p. 52. Available at: https://doi.org/10.1186/s40425-019-0528-x.

Cheng WC et al. (2019) ‘Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle’, Nature Immunology, 20(2), pp. 206–217. Available at: https://doi.org/10.1038/s41590-018-0290-0.

Grossert, Astrid et al. (2019) ‘A clinical trial of group-based body psychotherapy to improve bodily disturbances in post-treatment cancer patients in combination with randomized controlled smartphone-triggered bodily interventions (KPTK): study protocol’, BMC psychology, 7(1), p. 90. Available at: https://doi.org/10.1186/s40359-019-0357-1.

Ortega Sanchez G et al. (2019) ‘Toxicity associated with PD-1 blockade after allogeneic haematopoietic cell transplantation’, Swiss Medical Weekly, 149(45-46), p. w20150. Available at: https://doi.org/10.4414/smw.2019.20150.

Trefny MP et al. (2019) ‘A variant of a killer cell immunoglobulin-like receptor is associated with resistance to PD-1 blockade in lung cancer’, Clinical Cancer Research, 25(10), pp. 3026–3034. Available at: https://doi.org/10.1158/1078-0432.ccr-18-3041.

Stanczak, Michal A et al. (2018) ‘Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.’, The Journal of clinical investigation. 24.09.2018, 128(11), pp. 4912–4923. Available at: https://doi.org/10.1172/jci120612.

Ortega Sanchez G et al. (2018) ‘Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab.’, Journal for immunotherapy of cancer, 6(1), p. 85. Available at: https://doi.org/10.1186/s40425-018-0400-4.

Adams OJ et al. (2018) ‘Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.’, Glycobiology, 28(9), pp. 640–647. Available at: https://doi.org/10.1093/glycob/cwx108.

Pearce OMT and Läubli H (2018) ‘Cancer Immunotherapy.’, Glycobiology, 28(9), pp. 638–639. Available at: https://doi.org/10.1093/glycob/cwy069.

Ruhstaller T et al. (2018) ‘Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08).’, Annals of oncology : official journal of the European Society for Medical Oncology, 29(6), pp. 1386–1393. Available at: https://doi.org/10.1093/annonc/mdy105.

Wicki A et al. (2018) ‘First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).’, European journal of cancer (Oxford, England : 1990), 96, pp. 6–16. Available at: https://doi.org/10.1016/j.ejca.2018.03.012.

Läubli, Heinz et al. (2018) ‘Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events.’, Journal for immunotherapy of cancer, 6(1), p. 40. Available at: https://doi.org/10.1186/s40425-018-0353-7.

Borsig L. and Laubli H. (2018) ‘Cell adhesion during tumorigenesis and metastasis’. Elsevier, pp. 307–314. Available at: https://doi.org/10.1016/b978-0-12-801238-3.64991-7.

Läubli H et al. (2018) ‘The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors.’, Oncoimmunology. 26.10.2017, 7(2), p. e1386362. Available at: https://doi.org/10.1080/2162402x.2017.1386362.

Rothschild U et al. (2018) ‘Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.’, Swiss medical weekly, 148, p. w14625. Available at: https://doi.org/10.4414/smw.2018.14625.

Urech, Corinne et al. (2018) ‘Web-Based Stress Management for Newly Diagnosed Patients With Cancer (STREAM): A Randomized, Wait-List Controlled Intervention Study’, Journal of clinical oncology, 36(8), pp. 780–788. Available at: https://doi.org/10.1200/jco.2017.74.8491.

Hess V et al. (2017) ‘Capecitabine and Oxaliplatin Prior and Concurrent to Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer: Long-Term Outcome.’, Clinical colorectal cancer, 16(3), pp. 240–245. Available at: https://doi.org/10.1016/j.clcc.2016.07.008.